

**SIDAPHARM P.C.**  
Stageiriti 21 & 24, Em. Fili str.  
54352 Greece

Date: 20 May 2024

**Confirmation Letter**  
**Reference: GR\_016490\_2024\_02**

To whom it may concern,

Confirmation of the status of a formal application, written agreement, and appropriate surveillance in the framework of Regulation EU 2023/607 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices

This letter confirms that, HTCert, a Notified Body (NB) designated against Regulation (EU) 2017/745 (MDR) and identified by the number 2803 on NANDO, has received a formal application in accordance with Section 4.3, first subparagraph of Annex VII of MDR and has signed a written agreement in accordance with Section 4.3, second subparagraph of Annex VII of MDR with the following manufacturer:

SIDAPHARM P.C.  
21, Stageiriti & 24, Em. Filis str.  
54352 Greece  
SRN: GR-MF-000016490

Application ID: GR\_016490\_24\_03\_04  
Application Date: 14/03/2024  
Contract for MDR certification signed on 04/04/2024.

The devices covered by the formal application and the written agreement mentioned above are identified below. HTCert is also responsible for appropriate surveillance of the corresponding devices under the applicable Directive.

In the case of devices covered by certificates issued under Directive 90/385/EEC (AIMDD) or Directive 93/42/EEC (MDD) that expired after 26 May 2021 and before 20 March 2023, without having been withdrawn, this letter also confirms that the manufacturer signed the written agreement under MDR by the date of MDD/AIMDD certificate expiry; or provided evidence that a competent authority of a Member State had granted a derogation or exemption from the applicable conformity assessment procedure in accordance with Article 59(1) of MDR or Article 97(1) of the MDR respectively, by the 20 Mar 2023 for the relevant devices.

The transition timelines that apply to the devices covered by this letter, subject to the manufacturer's continued compliance to the other conditions specified in Article 120.3c of MDR (as amended by (EU) 2023/607), are shown below:

- 26 May 2026 for Class III custom-made implantable devices
- 31 December 2027 for Class III devices and Class IIb implantable devices excluding Well-established technologies (WET - sutures, staples, dental fillings, dental braces, tooth crowns, screws, wedges, plates, wires, pins, clips and connectors)

- 31 December 2028 for other Class IIb devices, Class IIa, Class I devices placed on the market in sterile condition or have a measuring function
- 31 December 2028 for devices not requiring the involvement of a notified body under MDD but requiring it under MDR (e.g., class I devices that qualify as re-usable surgical instruments)

On behalf of the Notified Body,



Filippos Kottis  
Certification Director

#### Devices covered by this letter

Device name or Basic UDI-DI (under MDR application)	MDR Device classification (as proposed by the manufacturer and verified at the pre- application stage)	If the MDR device is a substitute device, identification of the corresponding MDD device	MDD Certificate Reference(s) of the devices under MDR application, and the NB Identification
Ophthalmic Microsurgical Knives Brand Name: SIDAPHARM	Class IIa	n/a	1828C04210505 NB 2803
Hypromellose Ophthalmic Solution Brand Name: SIDA-HPMC 2%	Class IIb	n/a	1828C04210204 NB 2803
PVA Eye Spears Brand Names: SIDA-SPEARS, Olie Medical	Class Is	n/a	1828C04210204 NB 2803
Sodium Hyaluronate Ophthalmic Solution Brand Names: SIDA-VISC, Supralon	Class IIb	n/a	1828C04210204 NB 2803
Trypan Blue Ophthalmic Solution Brand Name: SIDA-BLUE	Class IIa	n/a	1828C04210505 NB 2803
Balanced Salt Solution Brand Name: SIDAPHARM BSS	Class IIb	n/a	1828C04210505 NB 2803
Ophthalmic Microsurgical Cannulas Brand Names: SIDAPHARM, Olie Medical	Class IIa	n/a	1828C04210505 NB 2803
Disposable Cartridge and Injector Brand Name: SIDA-JECT	Class IIa	n/a	1828C04210204 NB 2803

#### Confirmation Letter Revision History

Date	NB internal reference traceable to each version of the letter	Action
2024/04/04	GR_016490_2024_01	Initial issue
2024/05/20	GR_016490_2024_02	Addition of Brand Names